Studies in non-tumor cells have shown that ADAMTS6 can activate the latent transforming growth factor beta 1 (TGF-β1) and downstream SMAD2/3 pathway [7,8], whose role in EMT has been demonstrated in numerous studies [9,10,11,12,13]. Here, ADAMTS6 is linked to neoplasm.